CA
NZ
UK
AU
IND
US
Alliance Entertainment Holding Corporation filed a Form 8-K on November 10, 2026, reporting the voting results from its 2026 Annual Meeting of Stockholders held on November 5, 2026.
NET Power Inc. filed an 8-K on November 10, 2026, disclosing that its Board of Directors approved an amendment to the stock option held by President and Chief Operating Officer Marc Horstman, changing post-termination exercise rights effective November 4, 2026.
Aptera Motors Corp. filed a Form 8-K on November 10, 2026, disclosing the suspension and termination of its at-the-market offering prospectus and providing preliminary cash figures for the quarter ended September 30, 2026.
PepGen Inc. filed a current report on November 10, 2026, disclosing third quarter 2026 financial results and announcing positive Phase 2 FREEDOM2-DM1 data from its 10mg/kg multiple ascending dose cohort.
PDS Biotechnology Corporation filed a Form 8-K on November 10, 2026, disclosing that NantWorks exercised outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of common stock at an exercise price of $0.22 per share, generating approximately $3.9 million in gross proceeds …
Paul J. Hastings submitted an initial statement of beneficial ownership with the SEC on November 10, 2026, in connection with an event date of November 3, 2026, disclosing his status as a director of Azora Therapeutics, Inc. (DE), listed on NASDAQ:AZR.
Atossa Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $23.718 million for the nine months ended September 30, 2026, with cash and cash equivalents of $20.574 million at quarter end.
Nano-X Imaging Ltd filed a Form 6-K with the SEC on November 9, 2026, disclosing that its Board of Directors approved a strategic realignment and efficiency plan targeting a 25%-30% annualized reduction in operating expenses, alongside a global workforce reduction and four renewed strategic …
Nova Ltd. filed a Form 6-K on November 10, 2026, announcing that Chief Financial Officer Guy Kizner will participate in two investor conferences during November and December 2026.
Director Aida Habtezion filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 10, 2026, reporting her initial ownership position in Azora Therapeutics, Inc. as of the event date of November 3, 2026.
Please wait processing your request...